Analyst Price Targets — AMPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 9:25 pm | — | Barclays | $30.00 | $26.01 | TheFly | Amphastar initiated with an Equal Weight at Barclays |
| March 21, 2025 10:48 am | David Amsellem | Piper Sandler | $32.00 | $28.29 | TheFly | Amphastar price target lowered to $32 from $36 at Piper Sandler |
| August 8, 2024 8:06 am | David Amsellem | Piper Sandler | $66.00 | $43.31 | StreetInsider | Amphastar Pharmaceuticals (AMPH) PT Lowered to $66 at Piper Sandler |
| May 23, 2024 8:45 am | David Amsellem | Piper Sandler | $71.00 | $43.31 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Amphastar Pharmaceuticals (AMPH) |
| March 12, 2022 12:00 am | David Amsellem | Piper Sandler | $35.00 | $34.30 | Pulse 2.0 | Amphastar Pharmaceuticals (AMPH) Stock: Why The Price Jumped Up |
Latest News for AMPH
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner, SVP of Corp. Communication, will be presenting at the 25th Annual Needham Healthcare Conference on Tuesday, April 14, 2026, at 11:45 am ET. For access to the…
SG Americas Securities LLC purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 93,515 shares of the company's stock, valued at approximately $2,504,000. SG Americas Securities LLC owned about 0.20%
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $25.36 and traded as low as $19.27. Amphastar Pharmaceuticals shares last traded at $19.59, with a volume of 534,127 shares. Analysts Set
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Amphastar Pharmaceuticals (AMPH) is rated a Buy, with ~81% upside to a $33 fair value, despite margin pressures for 2026. AMPH faces declining sales in legacy products but expects mid- to high-single-digit revenue growth in 2026, led by Baqsimi and new launches. I estimate operating margin to dip to 22% in 2026 due to increased expenses, recovering to 26% by 2030 as higher-margin pipeline products ramp up.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMPH.
U.S. House Trading
No House trades found for AMPH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.